Neumora Therapeutics, Inc.

Industry

  • Pharmaceuticals
    • Vaccines
  • Biotechnology
    • Pharmacogenetics-Pharmacogenomics

Other Names/Subsidiaries

  • Abelian Therapeutics
  • Alairion
  • BlackThorn Therapeutics
  • RBNC Therapeutics
  • Syllable Life Sciences
See more in Biomedtracker

Latest on Neumora Therapeutics, Inc.

Scrip

No Ace For J&J’s VENTURA Studies Of Aticaprant In Depression

 
• By Alexandra Shimmings

Johnson & Johnson is discontinuing the Phase III VENTURA development program of its kappa opioid receptor (KOR) antagonist, aticaprant, as an adjunctive treatment for major depressive disorder (MD

Scrip

New Year’s Hangover: Neumora’s Phase III Failure In Depression Surprises

 
• By Joseph Haas

A bad case of post-holiday letdown set in for Neumora Therapeutics and its shareholders on 2 January as the brain disease-focused firm announced the failure of its kappa opioid receptor (KOR) antagoni

In Vivo

Nine Pivotal Studies To Look Out For In 2024

 
• By Alex Shimmings

DROP DOWN LINKS TO STUDIES: Sanofi’s GEMINI 1 & 2 And HERCULES Trials In Multiple Sclerosis Sanofi ended 2023 with a disappointment for its cancer therapy, tusamitamab ravtansine, but in 2024 eyes w

Scrip

10 Pivotal Studies To Look Out For In 2024

 
• By Alex Shimmings

DROP DOWN LINKS TO STUDIES: Sanofi’s GEMINI 1 & 2 And HERCULES Trials In Multiple Sclerosis Sanofi ended 2023 with a disappointment for its cancer therapy, tusamitamab ravtansine, but in 2024 eyes w